within Pharmacolibrary.Drugs.ATC.M;

model M04AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.28 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 9.96
  );

  annotation(Documentation(
    info ="<html><body><p>Probenecid is a uricosuric agent primarily used for the treatment of hyperuricemia associated with gout and gouty arthritis. The drug acts by inhibiting the renal tubular reabsorption of uric acid, thereby increasing its excretion. It is also known to increase plasma concentrations of some antibiotics (e.g., penicillins, cephalosporins) by inhibiting their renal excretion. Probenecid is an approved drug and in clinical use, though less commonly used today given the availability of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Drennan, PG, et al., &amp; Chambers, ST (2021). Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid. <i>British journal of clinical pharmacology</i> 87(12) 4681–4690. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14887&quot;>10.1111/bcp.14887</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33963595/&quot;>https://pubmed.ncbi.nlm.nih.gov/33963595</a></p></li><li><p>Davies, NM, &amp; Anderson, KE (1997). Clinical pharmacokinetics of naproxen. <i>Clinical pharmacokinetics</i> 32(4) 268–293. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199732040-00002&quot;>10.2165/00003088-199732040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9113437/&quot;>https://pubmed.ncbi.nlm.nih.gov/9113437</a></p></li><li><p>Wilson, RC, et al., &amp; Rawson, TM (2022). Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis. <i>The Journal of antimicrobial chemotherapy</i> 77(9) 2364–2372. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkac200&quot;>10.1093/jac/dkac200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35726853/&quot;>https://pubmed.ncbi.nlm.nih.gov/35726853</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M04AB01;
